NDTVCenter·
AstraZeneca Shares Sink 7% On $400 Billion Bristol Myers Buyout Talks
AstraZeneca investors questioned the benefits of a potential Bristol Myers Squibb merger despite expected gains in the US market and cost synergies.
Read at NDTV →
Business · 1 sources covering this
AstraZeneca Shares Sink 7% On $400 Billion Bristol Myers Buyout Talks
AstraZeneca investors questioned the benefits of a potential Bristol Myers Squibb merger despite expected gains in the US market and cost synergies.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://hindustansphere.com/embed/cluster/866ca2a371d63eaa5c8945c9fccecd030cb889b6" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="AstraZeneca Shares Sink 7% On $400 Billion Bristol Myers Buyout Talks"></iframe>
